Approval supported by two Phase 3 trials demonstrating a statistically significant reduction in constipation and abdominal pain in adult patients with IBS-C Novel MOA offers a new and differentiated option for patients with IBS-C and the physicians who treat them Discovered and developed by
The primary and all key secondary endpoints were met. Tenapanor in combination with binders met the primary endpoint demonstrating a statistically significant (p=0.0004) reduction of serum phosphorus compared to binders alone. Approximately two times more patients achieved the established serum
FREMONT, Calif. , Sept. 2, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, September 3 , at
AMPLIFY clinical trial to read out 3Q19 PHREEDOM clinical trial to read out 4Q19 FREMONT, Calif. , Aug. 9, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with
FREMONT, Calif. , May 30, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today announced that Mike Raab , president and chief executive
Two Pivotal Phase 3 readouts in 2H 2019 FREMONT, Calif. , May 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business
FREMONT, Calif. , March 14, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), today announced the appointment of Geoffrey A. Block , M.D., Vice President, Nephrology at Reata and former Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver
- Ardelyx's investigative agent for end-stage renal disease patients on dialysis represents first non-binder innovation to lower patients' phosphate levels, a critically important parameter that is correlated with morbidity and mortality - Ardelyx's approach leverages newly discovered pathway for
Company is poised for two Phase 3 readouts in 2H 2019 for tenapanor in hyperphosphatemia FREMONT, Calif. , March 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal
FREMONT, Calif. , Feb. 21, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab , president and chief executive officer of Ardelyx , will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:30 p.m. ET on Thursday, Feb.